Results 171 to 180 of about 100,395 (290)

Outcome-specific shifts in homocysteine-androgen correlations in polycystic ovary syndrome. [PDF]

Front Endocrinol (Lausanne)
Han Q, Zhao J, Li M, Xin M, Yin X, He J.
europepmc   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Social deprivation, race, and metabolic syndrome in patients with polycystic ovary syndrome. [PDF]

J Endocr Soc
Lee IT, King S, Sealy N, Rees J, Mumford SL, Hinkle SN, Dokras A.   +6 more
europepmc   +1 more source

Salidroside Ameliorates Polycystic Ovary Syndrome in Mice by Regulating the AKT/NF-κB/NLRP3-HAS2 Axis. [PDF]

Food Sci Nutr
Salidroside ameliorates PCOS via inhibiting the ROS‐AKT/NF‐κB axis and suppressing NLRP3 inflammasome activation. It disrupts the NLRP3–LAP‐TGFβ1 interaction to block TGF‐β‐SMAD2/3 signaling and consequent ovarian fibrosis. Together with hyaluronan synthase 2 (HAS2) downregulation, these effects alleviate inflammation and hyaluronan overaccumulation ...
Li JH, Shi SM, Liu LY, He YY, Jia GL, Qu LY, Chi ZC, Leng JH, Xu HJ, Lan T, Yan DL, Kong IK, Yu XF, Zhang MJ, Jin YX.   +14 more
europepmc   +2 more sources

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome. [PDF]

Front Endocrinol (Lausanne)
Chen Y, Sun X, Xia X, Chen K, Zeng F.
europepmc   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Exercise attenuates polycystic ovary syndrome development via improved mitochondrial proteostasis. [PDF]

Am J Physiol Endocrinol Metab
Shin C, Chen LW, Hossain MN, Li X, Islam S, Kou Z, Cui Q, de Avila JM, Zhu MJ, Du M.   +9 more
europepmc   +1 more source

A pituitary adenoma secreting high molecular weight adrenocorticotropin without evidence of Cushing's disease [PDF]

, 1987
Allolio, B., Kaulen, D., Reincke, Martin, Saeger, W., Winkelmann, W.   +4 more
core   +1 more source

Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine‐related adverse events (AEs). This study investigated the association between specific GLP‐1 RAs and these endocrine‐related AEs using a large‐scale pharmacovigilance ...
Nai Lee, Yun Kim
wiley   +1 more source